evipedia.ai
← Back

Thiamine for Health & Longevity

Evidence Review created on 08/12/2026 using AI4L / Opus 5

Also known as: Vitamin B1, Thiamin, Aneurin, Thiamine Hydrochloride, Thiamine Mononitrate, Benfotiamine, Sulbutiamine, Fursultiamine

Motivation

Thiamine (vitamin B1) is a water-soluble nutrient the body cannot manufacture and stores only in small amounts — roughly a month’s supply. It sits at the entrance to the pathway that converts food, especially carbohydrate, into usable energy, so a shortfall appears first in the tissues with the highest energy demand: nerves, brain, and heart. A severe shortfall causes well-described illnesses that were once widespread and still occur today.

Thiamine was the first vitamin to be isolated, and the search for it reshaped how nutrition and disease were understood. Modern interest reaches beyond preventing the classic deficiency disease. Researchers and clinicians have asked whether amounts far larger than any diet supplies affect tiredness, nerve damage, and memory decline — and whether people with heavy alcohol intake, weight-loss surgery, diabetes, or long-term fluid-tablet use quietly run short.

This review examines what the evidence establishes about thiamine and its fat-soluble relatives: where supplementation changes measurable outcomes, where it does not, how the available forms differ, and what the safety record looks like at doses far above dietary intake.

Benefits - Risks - Protocol - Conclusion

Expert commentary, narrative reviews, and primary trial reports that give a high-level overview of thiamine, its derivatives, and their proposed roles in health and longevity.

Note on the priority platforms: of the six, only Life Extension publishes openly readable content devoted to thiamine. FoundMyFitness covers vitamin B1 and blood glucose in Q&A #65, but that episode and its show notes are members-only, so the item is paywalled and not listed here. Direct searches of peterattiamd.com, hubermanlab.com, chriskresser.com, and lifespan.io returned no article, episode, or lecture devoted to thiamine or its derivatives.

Grokipedia

  • Thiamine

    Covers chemistry, transport, dietary sources, deficiency syndromes, and derivative forms, with intake and reference figures that are useful as a cross-check against supplement-industry summaries.

Examine

  • Thiamine (Vitamin B1)

    Gives evidence grades across heart failure, premenstrual symptoms, sepsis, dysmenorrhoea (painful periods), and type 2 diabetes, plus the dose ranges used in trials and the absence of a tolerable upper intake level.

ConsumerLab

ConsumerLab publishes no article dedicated solely to thiamine; its thiamine and benfotiamine testing is contained in the review linked above, and the detailed results table requires a paid membership.

Systematic Reviews

Systematic reviews and meta-analyses of thiamine and its derivatives, ordered from the healthy-ageing question outward to the clinical settings where the trials were actually conducted.

Trade-off coverage: the claimed effects (metabolic, cardiac, and cognitive) and the principal harm-side question (adverse events and longer intensive-care stay with intravenous dosing) are each represented above. No systematic review or meta-analysis of harms from oral thiamine supplementation in non-hospitalised adults exists, so that side of the trade-off is unrepresented in the pooled literature.

Mechanism of Action

Thiamine enters cells through two carriers, THTR-1 and THTR-2 (thiamine transporter proteins encoded by the genes SLC19A2 and SLC19A3), and is converted by thiamine pyrophosphokinase into thiamine diphosphate, the coenzyme that does the actual work. A separate carrier moves it into mitochondria, the cell’s energy-producing compartments.

Four enzyme systems depend on it: pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenase, which feed carbohydrate and amino-acid carbon into the energy-producing cycle; branched-chain ketoacid dehydrogenase, which degrades three essential amino acids; and transketolase, which links glucose breakdown to the pentose phosphate pathway (the route producing reducing power for antioxidant defence and the sugar backbone of DNA). Nerve tissue is affected first because it depends most heavily on glucose.

Two mechanistic accounts compete. The transketolase-activation hypothesis holds that supraphysiological thiamine diverts glucose intermediates away from the pathways generating advanced glycation end products (sugar-damaged proteins) and toward the pentose phosphate pathway, protecting small vessels and nerves. Critics note that benfotiamine, the derivative used to test this, reliably raises blood thiamine yet failed to alter nerve structure or function over 12 months.

Pharmacologically, thiamine has a plasma half-life of roughly 1–2 hours, a whole-body pool of about 25–30 mg turning over with a half-life of 9–18 days, and no receptor selectivity, since it acts as a cofactor. Distribution favours skeletal muscle, heart, liver, kidney, and brain. It is not a cytochrome P450 substrate (the liver enzyme family that breaks down most drugs); it is phosphorylated by thiamine pyrophosphokinase and cleared renally, largely unchanged at high doses.

Historical Context & Evolution

Thiamine’s original identity was the cure for beriberi, a disease of polished-rice diets that disabled navies and colonial garrisons from the 1870s onward. Takaki Kanehiro eliminated it from the Japanese navy in the 1880s by changing rations. Christiaan Eijkman reproduced the neuropathy in chickens fed polished rice and reversed it with the discarded husks, earning a share of the 1929 Nobel Prize. Casimir Funk coined “vitamine” in 1912, Jansen and Donath crystallised it in 1926, and Robert R. Williams synthesised it in 1936. Synthesis made it cheap, and flour enrichment from 1941 made classic beriberi rare in industrialised countries.

The move from replacement to pharmacology began soon after. Japanese researchers isolated allithiamine from garlic and developed fat-soluble derivatives — fursultiamine, then benfotiamine — to bypass the saturable intestinal transporter; benfotiamine was later licensed in Germany for nerve complaints and sulbutiamine marketed in France for exhaustion. From the 1960s Derrick Lonsdale reported that marginal deficiency on high-sugar diets produced neurological and behavioural symptoms responsive to high doses, in case series rather than controlled trials.

Mainstream nutrition largely set that work aside, but not by refuting it: the hypothesis that supraphysiological thiamine acts through mechanisms beyond repletion has never been tested in a large trial in the populations he described. Since then, controlled trials in diabetes, heart failure, and neuropathy have mostly returned null results, while the cognitive question has been reopened by a positive early trial and a large confirmatory trial now running.

Expected Benefits

High 🟩 🟩 🟩

Correction and Prevention of Thiamine Deficiency Syndromes

Thiamine reverses the disorders caused by its own absence: wet beriberi (a high-output form of heart failure), dry beriberi (peripheral nerve damage), and Wernicke encephalopathy (an abrupt brain injury causing confusion, unsteady gait, and disordered eye movements). The evidence base is the entire clinical literature on repletion rather than placebo-controlled trials, which are not conducted for ethical reasons. Relevance to this audience is conditional: it applies to sustained heavy alcohol intake, bariatric surgery, prolonged vomiting, long-term loop-diuretic use, dialysis, and severely restricted diets.

Magnitude: Pooled randomised trials in heart failure confirm that supplementation corrects measured thiamine deficiency, though cardiac endpoints did not change (He et al., 2024); for acute deficiency syndromes the literature reports case series and no controlled outcome figure.

Medium 🟩 🟩

Improvement in Blood Lipid Markers in Type 2 Diabetes

Across six randomised controlled trials (studies in which participants are assigned by chance to treatment or placebo) in 364 adults with type 2 diabetes, thiamine or benfotiamine at 100–900 mg daily left every blood-sugar measure unchanged but raised high-density lipoprotein, the particle associated with lower cardiovascular risk, and lowered triglycerides at one benfotiamine dose. The trials were small, single-centre, and ran up to three months, so this is a secondary laboratory finding rather than a demonstrated cardiovascular benefit.

Magnitude: High-density lipoprotein rose by a mean difference of 0.10 (95% confidence interval, the range within which the true value most likely lies, 0.10 to 0.20); benfotiamine 120 mg daily lowered triglycerides by 1.10 (95% confidence interval −1.90 to −0.30) (Muley et al., 2022).

Reduction of Chronic Fatigue ⚠️ Conflicted

In a crossover trial in 40 adults with inflammatory bowel disease in remission and severe chronic fatigue, high-dose oral thiamine at 600–1,800 mg daily, dosed by sex and body weight, reduced fatigue scores over four weeks. An identically designed trial by the same group in 34 adults with primary biliary cholangitis, an autoimmune liver disease, found no advantage over placebo. The conflict may reflect different fatigue mechanisms in the two conditions. Whether any effect extends to people without a chronic inflammatory illness is untested.

Magnitude: Fatigue fell by a mean 4.5 points (95% confidence interval 2.6 to 6.2) on thiamine against a 0.75-point rise on placebo in inflammatory bowel disease (Bager et al., 2021); in the liver-disease trial fatigue rose 0.3 points on thiamine and fell 1.4 points on placebo (Bager et al., 2024).

Low 🟩

Slowing of Cognitive Decline in Early Alzheimer’s Disease

In a 12-month phase IIa trial in 70 people with mild cognitive impairment or mild Alzheimer’s disease, benfotiamine 600 mg daily missed its primary cognitive endpoint but slowed worsening on a global dementia-severity rating. The signal was stronger in non-carriers of the APOE4 gene variant, which raises Alzheimer’s risk.

Magnitude: Worsening on the Clinical Dementia Rating scale was 77% lower than placebo (p = 0.034); the primary cognitive score declined 43% less but missed statistical significance (p = 0.125) (Gibson et al., 2020).

Reduction of Urinary Albumin Loss in Early Diabetic Kidney Disease

A placebo-controlled pilot trial in 40 adults with type 2 diabetes and small amounts of albumin in the urine found that thiamine 300 mg daily for three months reduced albumin loss without changing blood-sugar control, blood pressure, or blood lipids. It has not been replicated in a larger trial.

Magnitude: Urinary albumin excretion fell by a median 17.7 mg per 24 hours from baseline on thiamine (p < 0.001), with no significant change on placebo (Rabbani et al., 2009).

Symptom Relief in Diabetic Peripheral Neuropathy ⚠️ Conflicted

Short benfotiamine trials reported improved neuropathy symptom scores, and the compound is licensed for this indication in Germany. A rigorous 12-month trial using nerve-imaging, nerve-conduction, and clinical endpoints found no effect on any of them, despite confirming that blood thiamine levels rose.

Magnitude: Twelve months of benfotiamine 600 mg daily produced no difference in corneal nerve fibre length or in the morphometric, neurophysiological, and clinical secondary measures; only the Neuropathy Symptom Score trended toward improvement (p = 0.098) (Ziegler et al., 2026).

Relief of Primary Menstrual Pain

A randomised, double-blind, placebo-controlled trial in 556 young women with moderate to severe spasmodic period pain found thiamine 100 mg daily for 90 days largely abolished it, with the effect persisting two months after stopping. A Cochrane review judged the evidence low quality, and no independent replication exists.

Magnitude: After 90 days of thiamine 100 mg daily, 87% of participants were completely free of pain and a further 8% improved, while 5% showed no effect (Gokhale, 1996).

Faster Resolution of Shock in Critical Illness

This applies in an intensive-care setting rather than to daily supplementation, but it is the largest randomised evidence base for thiamine. Pooled trials show intravenous dosing shortens shock and lowers lactate and organ-failure scores without reducing deaths.

Magnitude: Shock duration was 11.4 hours shorter (95% confidence interval −20.2 to −2.7) and the organ-failure score 1.29 points lower; the mortality risk ratio was 0.89 (95% confidence interval 0.75 to 1.06) (Nakanishi et al., 2024).

Speculative 🟨

Motor and Non-Motor Symptom Improvement in Parkinson’s Disease

The basis is an uncontrolled open-label series of 50 patients given intramuscular thiamine twice weekly, reporting large symptom-score improvements. No blinding, no control group, and no independent replication (Costantini et al., 2015).

Preservation of Thiamine-Dependent Enzyme Activity in the Ageing Brain

Mechanistic only: activity of the thiamine-dependent enzymes declines in aged and neurodegenerative brain tissue, and animal work restores it with high doses. No human study tests this in healthy ageing.

Benefit-Modifying Factors

  • Baseline thiamine status: The single largest determinant. Every trial that corrected a measured deficit showed biochemical improvement; trials in replete participants showed none. Depleted status predicts response; normal status predicts its absence.

  • Transporter and activation gene variants: Rare loss-of-function variants in SLC19A2 and SLC19A3, the thiamine-transporter genes, and in TPK1, which encodes the enzyme that activates thiamine, produce disorders that respond only to pharmacological doses — the clearest proof that dose requirements vary by genotype.

  • Magnesium status: Magnesium is required by the enzyme that converts thiamine to its active coenzyme. Low magnesium can blunt the response to supplementation, which is why repletion protocols address both together.

  • Sex-based differences: Requirements scale with energy intake and body size, so reference intakes are higher for men (1.2 mg daily) than women (1.1 mg). The inflammatory-bowel fatigue trial dosed by sex and weight for this reason.

  • Pre-existing health conditions: Diabetes is associated with lower circulating thiamine markers; malabsorption, bariatric surgery, dialysis, heart failure treated with loop diuretics, and alcohol use disorder all increase losses or requirements and shift the expected benefit upward.

  • Age-related considerations: Intake, absorptive capacity, and body stores decline with age, and older adults carry the heaviest burden of the medications that deplete thiamine, so the probability of a correctable deficit rises across the target range.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Hypersensitivity Reactions to Injected Thiamine

Injected thiamine can provoke itching, local irritation, wheeze, or, rarely, anaphylaxis, a sudden whole-body allergic reaction. The mechanism is an immune response to the molecule or to formulation excipients. It is the reason intravenous doses are diluted and infused slowly in a monitored setting. Oral thiamine has not been associated with this pattern, so it is a hazard of clinical administration rather than of supplementation, and it is reversible with prompt treatment.

Magnitude: Among 989 patients given parenteral thiamine, one major reaction (about 0.1%) and 11 minor reactions (1.1%) were recorded (Wrenn et al., 1989).

Mild Gastrointestinal and Nonspecific Effects at High Oral Doses

Nausea, abdominal discomfort, headache, and restlessness are what gram-level oral dosing produces, and they represent the ceiling of what controlled trials have found. In crossover trials at 600–1,800 mg daily and in phase I escalation to 1,200 mg of benfotiamine, adverse-event rates matched placebo and no dose-limiting toxicity emerged. No tolerable upper intake level has been established for thiamine, reflecting an absence of documented toxicity from food or supplements. Effects resolve on stopping.

Magnitude: Only mild and transient adverse events occurred at 600–1,800 mg daily (Bager et al., 2021), and phase I incidence and severity were similar between benfotiamine and placebo (Sheng et al., 2021).

Slightly Longer Intensive Care Stay With Intravenous Thiamine in Critical Illness

Pooled analysis of 35 randomised trials found intravenous thiamine associated with a small increase in intensive-care length of stay, graded high certainty — the only harm signal in that literature carrying such a grade. The mechanism is unknown and may reflect longer survival in shock rather than injury. It has no established bearing on oral supplementation in ambulatory adults.

Magnitude: Mean difference 0.40 days longer (95% confidence interval 0.01 to 0.79) (Nakanishi et al., 2024).

Medium 🟥 🟥

Loss of an Interpretable Baseline Once Supplementation Starts

Supplementation raises every measurable thiamine fraction in blood within days, so starting a high-dose protocol before testing forfeits the ability to establish whether a deficit existed. Because perceived response is the main way people judge these protocols, this makes a corrected deficiency indistinguishable from a placebo response and can lock in indefinite dosing that serves no purpose. Several weeks of washout are needed before testing becomes informative again.

Magnitude: Benfotiamine 600 mg daily raised all six measured thiamine analytes in blood relative to placebo (p ≤ 0.003) (Ziegler et al., 2026).

Low 🟥

Elevated Liver Enzyme and Urinary White Cells With High-Dose Benfotiamine

The two most frequent treatment-related findings in phase I dose-escalation of benfotiamine were a rise in alanine aminotransferase, a liver enzyme, and white blood cells in urine. Both were detected on laboratory monitoring rather than experienced as symptoms.

Magnitude: Reported as the commonly observed drug-related adverse events across single doses to 1,200 mg and repeated dosing to 600 mg twice daily, with no incidence figure given (Sheng et al., 2021).

Stimulation, Agitation, or Disrupted Sleep With Sulbutiamine

Sulbutiamine, a fat-soluble derivative that crosses into the brain readily, has been associated with restlessness, irritability, and insomnia, and escalating self-administration has been described. These effects are not reported for thiamine hydrochloride or benfotiamine at comparable doses.

Magnitude: Not quantified in available studies.

Speculative 🟨

Transient Symptom Flare When Starting High Doses in Depleted Individuals

Practitioners using pharmacological thiamine describe a brief worsening of fatigue, anxiety, or muscle symptoms in the first days, attributed to an abrupt rise in energy metabolism. The basis is clinical report only.

Imbalance With Magnesium and Other B Vitamins at Sustained High Doses

Activating thiamine and running its dependent enzymes consumes magnesium and operates alongside riboflavin. Sustained gram-level dosing is argued to unmask shortfalls of both. Mechanistic reasoning and case reports only.

Risk-Modifying Factors

  • Prior hypersensitivity and atopy (an inherited tendency to allergy): A documented reaction to any thiamine preparation is the strongest single predictor of a further reaction. Existing allergic disease raises baseline risk for the parenteral route specifically.

  • Genetic variants: No common polymorphism is established as modifying adverse effects. The transporter variants that alter requirement affect how much is needed, not how well high doses are tolerated.

  • Baseline biomarker levels: Pre-existing elevation of liver enzymes makes the benfotiamine liver-enzyme signal harder to interpret, and reduced kidney function limits the renal clearance that handles excess thiamine.

  • Sex-based differences: No consistent sex difference in adverse effects has been reported across the randomised trials, which enrolled both sexes and dosed by weight; the absence of a signal reflects small trial sizes rather than demonstrated equivalence.

  • Pre-existing health conditions: Advanced kidney disease slows clearance of gram-level doses, and liver disease impairs both storage and activation, so both alter the exposure achieved from a given dose.

  • Age-related considerations: Older adults accumulate reduced kidney clearance and more concurrent medications, which raises exposure at a fixed dose and increases the chance of an interaction being mistaken for a side effect.

Key Interactions & Contraindications

  • Loop diuretics (furosemide, bumetanide, torsemide): Increase urinary thiamine loss. Severity: monitor. Consequence: progressive depletion, documented in long-term heart-failure use (Katta et al., 2016). Mitigation: periodic status testing or routine repletion.

  • Metformin: A substrate and inhibitor of the thiamine transporter THTR-2, competing for intestinal uptake (Liang et al., 2015). Severity: caution. Consequence: reduced absorption. Mitigation: separate doses by several hours.

  • Other transporter-inhibiting prescription drugs: A screen identified numerous marketed drugs that block THTR-2, fedratinib being the clearest clinical case (Vora et al., 2020). Severity: caution to contraindication. Consequence: acquired deficiency. Mitigation: periodic thiamine status testing.

  • Fluorouracil-based chemotherapy: Interferes with conversion of thiamine to its active coenzyme. Severity: caution. Consequence: precipitation of acute deficiency. Mitigation: repletion is standard supportive care during treatment.

  • Alcohol: Impairs absorption, hepatic storage, and activation simultaneously. Severity: caution, and absolute contraindication to relying on diet alone. Consequence: Wernicke encephalopathy. Mitigation: routine supplementation with sustained intake.

  • Antacids and alkalinising agents (calcium carbonate, magnesium hydroxide, sodium bicarbonate): Thiamine degrades at alkaline pH and depends on an acidic environment for uptake. Severity: minor. Consequence: reduced absorption. Mitigation: dose separately from these products.

  • Over-the-counter caffeine and tannin-rich preparations: Polyphenols in tea, coffee, and betel preparations oxidise thiamine in the gut. Severity: minor. Consequence: reduced absorption at habitual high intakes. Mitigation: separate dosing from these beverages.

  • Sulfite-containing products and raw thiaminase foods: Sulfite preservatives cleave thiamine; raw fish, shellfish, and ferns contain thiaminase enzymes. Severity: minor to moderate. Consequence: degradation before absorption. Mitigation: cooking destroys thiaminase.

  • Supplement combinations with additive effects: Magnesium enables thiamine activation; alpha-lipoic acid and benfotiamine act on overlapping glucose-handling pathways, as do chromium and berberine. Severity: monitor. Consequence: additive lowering of blood glucose. Mitigation: home glucose monitoring when combined with glucose-lowering medication.

  • Other interventions: Bariatric surgery, prolonged parenteral nutrition, and high-dose intravenous glucose all raise thiamine demand abruptly. Severity: caution. Consequence: refeeding-associated deficiency. Mitigation: thiamine before carbohydrate loading.

Populations who should avoid Thiamine:

  • Anyone with documented anaphylaxis or severe hypersensitivity to a thiamine preparation — absolute contraindication to re-exposure by any route.

  • People with advanced kidney disease (estimated glomerular filtration rate, a measure of kidney function, below 30 mL/min/1.73 m²) taking gram-level doses — clearance is reduced and no dosing data exist.

  • People with suspected acute Wernicke encephalopathy — this requires parenteral treatment under medical supervision, not oral self-supplementation.

  • Pregnancy and lactation at doses above reference intakes — dietary-level intake is established as necessary, but gram-level dosing is untested.

Risk Mitigation Strategies

  • Test before starting: Whole-blood thiamine diphosphate measured before the first dose preserves the only chance to distinguish deficiency correction from placebo response, which becomes impossible within days of starting.

  • Start at 100 mg and escalate over weeks: Beginning at 100 mg daily and increasing in 100–300 mg steps every 1–2 weeks limits the transient flare of fatigue or anxiety reported when depleted individuals begin high doses.

  • Correct magnesium first: Supplying 200–400 mg elemental magnesium daily before or alongside thiamine addresses the cofactor requirement for thiamine activation and reduces the imbalance risk described at sustained high doses.

  • Restrict parenteral dosing to clinical settings: Injected thiamine carries the only serious documented reaction risk. Confining it to supervised administration with slow dilute infusion eliminates the hazard from routine use.

  • Monitor liver enzymes on high-dose benfotiamine: Checking alanine aminotransferase at 8–12 weeks and then every 6–12 months detects the rise seen in dose-escalation studies before it becomes clinically relevant.

  • Set a stopping rule: Defining in advance a 12-week trial with a specific outcome measure prevents indefinite dosing that no longer serves a purpose and avoids attributing unrelated changes to the supplement.

  • Separate from depleting agents: Dosing several hours apart from metformin, antacids, tea, and coffee avoids the absorption losses that make an apparently adequate dose ineffective.

Therapeutic Protocol

  • Dietary replacement dose: Reference intakes are 1.2 mg daily for men and 1.1 mg for women. Multivitamins typically supply 1.5–25 mg, which covers the dietary requirement several times over.

  • Repletion dose for documented deficiency: Conventional practice uses 50–100 mg of thiamine hydrochloride daily by mouth for a documented deficit, with parenteral dosing reserved for malabsorption or acute neurological presentation.

  • Pharmacological approach: The alternative tradition, developed by Lonsdale and Costantini and promoted by Overton, treats thiamine as a metabolic stimulant at 300–1,800 mg daily. Both approaches are in current use; neither is established as the default.

  • Doses used in trials: Trials employed 100–500 mg of plain thiamine, 300 mg twice daily of benfotiamine, and 600–1,800 mg daily of thiamine hydrochloride for fatigue, over durations from one month to three years.

  • Best time of day: Morning and midday dosing is conventional, because thiamine supports energy metabolism and the derivatives that enter the brain readily have been linked to sleep disruption when taken late.

  • Half-life and dosing frequency: Free thiamine clears from plasma within a few hours while the whole-body pool turns over across 9–18 days, so daily consistency matters more than precise timing.

  • Split versus single dosing: Intestinal transport saturates in the low-milligram range, so gram-level doses are conventionally split two or three times daily; absorption above that relies on passive diffusion.

  • Choice of form: Thiamine hydrochloride and mononitrate are the cheapest and best characterised. Benfotiamine achieves higher blood levels; fursultiamine and sulbutiamine enter the brain more readily but carry less safety data.

  • Genetic polymorphisms: Variants in SLC19A2, SLC19A3, and TPK1 define the rare disorders that require pharmacological doses. No common variant has been validated as a routine guide to dose selection.

  • Sex-based differences: The fatigue trials dosed by sex and body weight, with women receiving the lower end of the 600–1,800 mg range. No sex difference in efficacy has been demonstrated.

  • Age-related considerations: Older adults show lower intake, reduced absorption, and reduced kidney clearance, which argues for starting at the low end of any range and reassessing status rather than escalating on symptoms.

  • Baseline biomarkers: Whole-blood thiamine diphosphate, magnesium, and liver enzymes before starting determine both whether a deficit exists and whether the cofactor and clearance conditions for a fair trial are met.

  • Pre-existing conditions: Malabsorption, bariatric surgery, alcohol use disorder, and long-term diuretic use all favour the repletion approach and often require higher or parenteral dosing to achieve the same blood levels.

Discontinuation & Cycling

  • Lifelong versus short-term: Repletion for an ongoing cause — bariatric surgery, sustained diuretic use, malabsorption — is indefinite. Symptom-driven high-dose use is better framed as a defined trial with a stopping point.

  • Withdrawal effects: None are documented. Thiamine produces no dependence, and stopping returns blood levels toward baseline over days to weeks as the body pool turns over.

  • Tapering: No taper is required on pharmacological grounds. Stepping down over 1–2 weeks is used mainly to make any return of the original symptoms easier to attribute.

  • Cycling for efficacy: No tolerance has been demonstrated, so cycling is not required to maintain effect. Scheduled breaks serve a different purpose — confirming the supplement is still doing something.

  • Reassessment after stopping: Blood thiamine markers need several weeks after discontinuation before they again reflect dietary status rather than the supplement.

Sourcing and Quality

  • Form selection: Thiamine hydrochloride and thiamine mononitrate are pharmacopoeial commodities with essentially identical behaviour. Benfotiamine, fursultiamine, and sulbutiamine are distinct compounds and are not interchangeable with them by milligram.

  • Third-party testing: Independent verification marks such as USP Verified, NSF Certified for Sport, or ConsumerLab approval address the failure mode that testing actually finds in this category — label inaccuracy rather than contamination.

  • Label accuracy record: ConsumerLab’s testing of 26 B-vitamin products found five providing significantly more or less than labelled, which is the main quality argument for buying verified products rather than the cheapest available.

  • Reputable suppliers: Thorne, Pure Encapsulations, Doctor’s Best, and Life Extension are commonly used and participate in third-party programmes. Life Extension both publishes on benfotiamine and sells it, a conflict worth weighting.

  • Benfotiamine specifics: Purity and the absence of related thiamine disulfides matter more here than for the simple salts, and a certificate of analysis identifying the assay method is the practical check.

  • Excipients and preservatives: Sulfites degrade thiamine, so sulfite-free formulations and opaque, sealed packaging preserve potency; thiamine is also degraded by heat, light, and alkaline conditions.

Practical Considerations

  • Time to effect: Blood levels rise within days. Where a genuine deficit exists, neurological signs can improve within hours to days on parenteral dosing, while fatigue and symptom changes in the trials were assessed at four weeks.

  • Common pitfalls: Starting before testing, attributing improvement to thiamine without a stopping trial, assuming benfotiamine and thiamine hydrochloride are interchangeable by milligram, and continuing indefinitely without a defined outcome.

  • Regulatory status: In the United States thiamine and benfotiamine are dietary supplements. In Germany benfotiamine is a registered medicine for nerve complaints, and sulbutiamine is a prescription product in France — the same molecules occupy different regulatory categories by country.

  • Cost and accessibility: Thiamine hydrochloride is among the cheapest supplements available, typically a few dollars a month; benfotiamine costs more but remains inexpensive. Neither is difficult to obtain.

  • Structural incentives in the evidence base: Thiamine is off-patent and cheap, so no manufacturer has an incentive to fund large outcome trials, and payers have no cost incentive to favour it over patented alternatives. The large trials now running are publicly and charitably funded.

Interaction with Foundational Habits

  • Sleep: Direct and bidirectional. Deficiency produces fatigue and irritability that degrade sleep quality, while the brain-penetrant derivatives — sulbutiamine in particular — have been linked to insomnia when taken in the evening. Morning and midday dosing avoids the latter, and no evidence indicates plain thiamine improves sleep in replete individuals.

  • Nutrition: Direct and central. Requirements rise with carbohydrate and alcohol intake and fall on lower-carbohydrate patterns. Legumes, whole grains, pork, nutritional yeast, and enriched flour are the reliable food sources; raw fish, ferns, sulfite-preserved foods, tea, and coffee reduce availability. Absorption improves when doses are spread across meals.

  • Exercise: Indirect. Higher energy turnover raises thiamine demand proportionally, and endurance training increases losses through sweat and urine. No evidence indicates supplementation enhances performance or blunts training adaptation in replete athletes, and no timing relationship to workouts is established.

  • Stress management: Indirect. Thiamine has no demonstrated effect on cortisol or the stress response, but deficiency produces apathy, anxiety, and cognitive slowing that resemble stress-related states, and psychological stress raises metabolic demand. The practical implication is diagnostic — deficiency can be mistaken for burnout.

Monitoring Protocol & Defining Success

Testing before the first dose is what makes any later judgement possible, because supplementation raises every blood marker within days. A useful baseline comprises whole-blood thiamine diphosphate, a red-cell transketolase activation coefficient where the laboratory offers one, magnesium, a liver panel, fasting glucose with glycated haemoglobin, and — where diabetes is present — a urinary albumin-to-creatinine ratio. Repeat testing follows the purpose: for repletion of a documented deficit, whole-blood thiamine diphosphate at 4–8 weeks confirms correction; for open-ended high-dose use, liver enzymes and magnesium at 8–12 weeks and then every 6–12 months detect the two findings that trials have flagged. Symptom-driven trials without a measured deficit are best run as time-limited blocks with a predefined stopping point.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Whole-blood thiamine diphosphate 90–180 nmol/L The direct measure of the active coenzyme and body status Conventional reference ranges start near 67 nmol/L, well below the functional target; sample must be protected from light and frozen promptly
Erythrocyte transketolase activation coefficient (ETKAC) Below 1.15 Functional test of whether the enzyme is short of its coenzyme ETKAC is a red-cell enzyme test; conventional cut-off for deficiency is above 1.25; availability is limited and it is normalised by recent supplementation
Serum or red-cell magnesium Red-cell magnesium 5.0–6.5 mg/dL Required cofactor for converting thiamine to its active form Serum magnesium is insensitive; red-cell measurement is preferred and is unaffected by fasting state
Alanine aminotransferase (ALT) 10–26 U/L Detects the liver-enzyme rise reported on high-dose benfotiamine ALT is a liver enzyme; conventional upper limits reach 40–55 U/L, far above the functional target; best paired with gamma-glutamyl transferase
Fasting glucose and glycated haemoglobin (HbA1c) Fasting glucose 75–90 mg/dL; HbA1c 4.8–5.4% Tracks the metabolic endpoint that supplementation trials targeted HbA1c is average blood sugar over about three months; fasting glucose requires 8–12 hours fasting, while HbA1c is unaffected by fasting and can be drawn at any time
Serum lactate Below 1.5 mmol/L at rest Rises when the thiamine-dependent step in energy metabolism is limited Must be drawn without a tourniquet and without prior exercise; a screening rather than confirmatory marker
Urinary albumin-to-creatinine ratio Below 10 mg/g The endpoint that improved in the diabetic kidney pilot trial First-morning sample preferred; a single elevated result requires confirmation on a second sample

Qualitative markers worth tracking alongside laboratory values:

  • Daytime energy and the presence or absence of post-meal fatigue after carbohydrate-rich meals
  • Cognitive clarity, word-finding, and short-term recall
  • Sleep quality and time to fall asleep, particularly with brain-penetrant derivatives
  • Exercise recovery and unexplained shortness of breath on exertion
  • Numbness, tingling, or burning in the hands and feet
  • Mood stability, apathy, and irritability

Emerging Research

  • Largest outcome trial ever run: COLT-HF (NCT05873881) randomises 2,500 participants with heart failure from ischaemic heart disease to thiamine mononitrate 300 mg daily or none, in a factorial design with colchicine. Primary endpoint: cardiovascular death or a heart-failure event over 3.5 years, with primary completion in June 2027.

  • Confirmatory cognition trial: BenfoTeam (NCT06223360) is testing benfotiamine at 600 or 1,200 mg daily against placebo in 406 participants with early Alzheimer’s disease over 72 weeks, with cognitive and global-function co-primary endpoints. Primary completion is December 2027.

  • Head-to-head neuropathy comparison: A phase 4 trial (NCT07708233) compares benfotiamine against a combined B1–B6–B12 preparation in 66 participants with diabetic peripheral neuropathy, with primary completion in June 2027.

  • Surgical and vascular questions: An early-phase trial (NCT06326996) is testing thiamine in 52 patients undergoing coronary artery bypass grafting, and a companion trial (NCT06322212) examines blood-brain barrier integrity in type 2 diabetes.

  • Evidence weakening the case: The 12-month BOND trial found benfotiamine raised every thiamine fraction in blood yet changed no nerve-structure, nerve-conduction, or clinical endpoint (Ziegler et al., 2026), the most direct test of the transketolase hypothesis to date and a null result.

  • Drug-induced depletion mapping: Systematic screening of marketed drugs for inhibition of the thiamine transporter (Vora et al., 2020) could reframe part of the deficiency question as one caused by medical treatment, and would strengthen the case for status testing in people on multiple medications.

  • Open question on brain delivery: Whether any oral form raises the active coenzyme inside human brain tissue remains unresolved, and imaging or cerebrospinal-fluid work answering it would determine whether the cognitive findings have a plausible route of action.

Conclusion

Thiamine is an essential nutrient with an unusually clean safety record and an unusually mixed record of benefit beyond correcting a shortfall. Where a genuine deficit exists — from heavy alcohol intake, weight-loss surgery, long-term fluid tablets, poor absorption, or a restricted diet — replacing it reverses serious nerve, brain, and heart problems, and that part of the picture is not in dispute. The proposition that much larger amounts help people who are already well supplied is where the evidence thins out.

Carefully conducted trials have repeatedly shown that supplementation raises blood levels reliably while leaving the outcomes it was expected to change untouched: blood sugar, heart function, and nerve damage all failed to improve in the better trials. Against that, a fatigue trial in one inflammatory condition, an early memory trial, a small kidney trial, and an old trial in menstrual pain produced positive signals that have not yet been repeated. The main risks are minor and reversible, and the serious ones belong to the injected route in hospital settings.

Much of the enthusiastic material comes from parties who sell the product or the protocols, and the cheapness of the compound means nobody has a commercial reason to settle the question. Two large publicly funded trials should resolve the heart and memory questions within the next few years. Until then, the honest summary is a safe intervention with a narrow, well-defined use and a wider set of claims still awaiting support.

Top - Benefits - Risks - Protocol